GlassScriptPhysician profile
Nedal S Mejalli
NPI 1811004385
$3,890.58
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $1,171 · 2021: $1,267.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,197.92 | 2019-2021 | |
| Novo Nordisk INC | $569.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.73 | 2019-2021 | |
| Alkermes, INC. | $336.17 | 2019-2021 | |
| Gilead Sciences, INC. | $332.86 | 2019-2021 | |
| Lilly USA, LLC | $168.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.28 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $89.21 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $84.18 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $69.18 | 2021 | |
| Abbvie INC. | $43.44 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $41.97 | 2019 | |
| Melinta Therapeutics, LLC | $39.81 | 2019 | |
| Ironshore Pharmaceuticals INC. | $39.67 | 2019-2020 | |
| Pfizer INC. | $39.54 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $31.54 | 2021 | |
| Sanofi Pasteur INC. | $29.83 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.10 | 2020 | |
| Allergan, INC. | $24.32 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $17.75 | 2020 | |
| Mdd US Operations, LLC | $16.96 | 2020 | |
| Agile Therapeutics, INC. | $15.90 | 2021 | |
| Uswm, LLC | $15.08 | 2021 | |
| Glaxosmithkline, LLC. | $14.86 | 2020 | |
| Astellas Pharma US INC | $14.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nedal Mejalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.